Darrell, very good point. They should use an IV butterfly needle. I hold it steady while the nurse pushes the drug.

For those who take injections in the tummy make sure they use IV to inject and not the syringe to skin. It will stop swelling and limit the bruising

Howeler, have head great things about the bispecific drug. What is the name of the one you are on, is it Talvey? Sounds like a tri-specific might be available soon.

Leading Tri-Specific Candidates in Clinical Development

JNJ-5322 (JNJ-79635322):Targets: BCMA, GPRC5D, and CD3.Status: Evaluated in Phase 1 clinical trials for relapsed/refractory multiple myeloma, showing high response rates comparable to CAR-T therapy.

IBI3003:Targets: GPRC5D, BCMA, and CD3.Status: Developed by Innovent, it received FDA Fast Track designation in January 2026 and is advancing through early-to-late stage global clinical trials.

ISB 2001 (ISB201):Targets: BCMA, CD38, and CD3.Status: A first-in-class tri-specific T-cell engager designed to maintain high-affinity binding even when target antigen levels are low.

Potential Benefits Over Current Therapies
Overcoming Resistance: Hitting two myeloma markers at once prevents cancer cells from escaping treatment by downregulating a single antigen.
Reduced Toxicity: Enhanced avidity allows for optimized or lower dosing configurations, which may minimize severe on-target, off-tumor side effects.

I am at a roadblock right now for my treatment. ADR to Revlimid, Velcade, Darzalex FasPro and IV drip, and Zometa🫩
Currently on a drug holiday as long as lab work remains acceptable for what is expected for high-risk, IgA, kappa light chain, multiple myeloma. Not necessary in all "normal" ranges.
Still get monthly🩸blood draws and see my hematologist/oncologist every other month. Will see my MM specialist in November unless something critical changes.

Hi chrisbaird, I have also gone through same treatment for 2 years and it worked great. My best wishes.